在停止使用奥西洛德罗斯塔特后,长期上腺皮质阻塞
Jonathan Poirier1, Fidéline Bonnet-Serrano2,3, Louis Thomeret3
1Assistance Publique-Hôpitaux de Paris, Service d'Endocrinologie et Maladies Métaboliques -Hôpitaux universitaires Paris-Centre, Paris F-75014, France.
European journal of endocrinology
|June 10, 2023
概括
奥西洛德罗斯塔特是一种新的高皮质醇药物,在停止治疗后可能导致长时间的上腺皮质阻塞. 停止后监测上腺功能对于预防上腺危机至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥西洛德罗斯塔特是最近批准用于管理高皮质醇症的药物.
- 这项研究研究了一种与停止治疗奥西洛德洛斯塔特相关的新型不良事件.
研究的目的:
- 为了描述之前未经记录的奥西洛德罗斯塔特的副作用:长时间的上腺皮质阻塞.
- 强调在停止使用奥西洛德罗斯塔特药物后需要继续监测.
主要方法:
- 病人的病历的回顾性审查.
- 分析患者特征和荷尔蒙剂量,以奥西洛德罗斯塔特控制的高皮质醇症患者治疗中断.
主要成果:
- 三名患者表现出持续的上腺皮质阻塞,持续时间为6周至9个月.
- 阻塞发生不论奥西洛德罗斯塔特剂量 (2-10毫克/天) 或总治疗持续时间.
结论:
- 长期上腺皮质阻塞是停止使用奥西洛德罗斯塔特后新发现的一种不良事件.
- 在停止使用奥西洛德罗斯塔特药物后,继续监测上腺功能是必不可少的,以减轻上腺危机的风险.
相关概念视频
Desensitization and Tachyphylaxis
1.9K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.9K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
892
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
892
Adrenal Gland Disorders
1.6K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.6K
Hypothalamic-Pituitary Axis
60.7K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
60.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
895
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
895
Adrenergic Antagonists: ɑ and β-Receptor Blockers
524
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
524


